Fidaxomicin for treatment of clostridium difficile infection in clinical practice: a prospective cohort study in a french university hospital - Université de Lille Accéder directement au contenu
Article Dans Une Revue Infection Année : 2017

Fidaxomicin for treatment of clostridium difficile infection in clinical practice: a prospective cohort study in a french university hospital

Résumé

OBJECTIVE: Two randomized controlled trials (RCTs) showed the non-inferiority of fidaxomicin compared with vancomycin for Clostridium difficile infection (CDI) treatment and its superiority regarding recurrence rate. The aim of this study was to evaluate fidaxomicin's efficacy in clinical practice. METHODS: This single-center prospective cohort study included hospitalized patients treated with fidaxomicin for CDI. Demographic, clinical and biological data were collected. Primary outcome was efficacy of fidaxomicin (clinical cure, recurrence and global cure) at 10 weeks. Secondary outcome was efficacy among different subgroups. RESULTS: Ninety-nine patients were included: 42 severe CDI, 16 complicated CDI and 41 recurrent CDI. Rates of clinical cure, recurrence and global cure were 87, 15 and 59%, respectively. Subgroup analysis showed a higher recurrence rate for patients with recurrent CDI compared with first episode (8 vs. 26%; p = 0.04). Binary toxin was associated with severe/complicated CDI (80 vs. 50%; p < 0.01) and recurrence (32 vs. 7%; p < 0.01). Fidaxomicin was used as a first line for 83% of the patients with recurrence and for only 52% of first episodes even though 86% had recurrence's risk factors. CONCLUSIONS: Compared with RCTs, fidaxomicin in real world is used for patients with more severe and recurrent CDI, but clinical cure and recurrence rates were similar. Comparative studies are needed in these specific subgroups. Our data also illustrate clinicians' difficulty to define a "patient at risk for recurrence" among the first episodes. Finally, we showed that binary toxin could be important in the screening for severity and recurrence risks.
Fichier non déposé

Dates et versions

hal-02559059 , version 1 (30-04-2020)

Identifiants

Citer

Marie Pichenot, Rozenn Hequette-Ruz, Rémi Le Guern, Bruno Grandbastien, Clement Charlet, et al.. Fidaxomicin for treatment of clostridium difficile infection in clinical practice: a prospective cohort study in a french university hospital. Infection, 2017, Infection, 45, pp.425-431. ⟨10.1007/s15010-017-0981-8⟩. ⟨hal-02559059⟩

Collections

UNIV-LILLE
42 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More